{"cmr":"ch-cm-kg/SIX/BIOV","since":null,"total":20,"cursor":0,"limit":50,"next_cursor":null,"events":[{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-10-29","event_type":"ad_hoc","title":"BioVersys announces first patient first visit in Phase 2b RIV ...","category":"ad-hoc","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/de/news/ad-hoc/bioversys-announces-first-patient-first-visit-in-phase-2b-riv-care-trial-of-bv100/578dc298-5e66-4843-b63c-4f6fb0c3d4ae_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"bNNQYEaTtxAZmCHQJG_YYFDN_7DZ-LH3fXDCju7CkWyAOpaHkEGB-RIyhUfvqrAay1LoqT2-7XZD-InVDMvoAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-10-29","event_type":"ad_hoc","title":"BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100 | Ad-hoc - EQS News","category":"ad-hoc","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/ad-hoc/bioversys-announces-first-patient-first-visit-in-phase-2b-riv-care-trial-of-bv100/578dc298-5e66-4843-b63c-4f6fb0c3d4ae_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"yJq263IbCfJWYgGrhY_4JL-XT78v-dhkBkYgWcFf-CAFIE0WhuRfYsaRCx-odcxpMeNO-FL_sMrUS45zTSCcAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-10-22","event_type":"corporate_news","title":"BioVersys’ BV100 Phase 2 exploratory data selected for rapid fire and poster presentations at IDWeek 2026 | Corporate - EQS News","category":"corporate","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/bioversys-bv100-phase-2-exploratory-data-selected-for-rapid-fire-and-poster-presentations-at-idweek-2026/aa871064-a5b0-4c83-a1cb-623835bb9d35_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Jr60Cdg97iEJEhm9aKCQcCq8eZVPXo6k47-GmTMasoHTAixBFapnwdGDPZNOD6cPL-_pjgRpayRbR53NUuflDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-10-22","event_type":"corporate_news","title":"BioVersys' BV100 Phase 2 exploratory data selected for ...","category":"corporate","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/de/news/corporate/bioversys-bv100-phase-2-exploratory-data-selected-for-rapid-fire-and-poster-presentations-at-idweek-2026/aa871064-a5b0-4c83-a1cb-623835bb9d35_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"OL226Pt4j4zIN-xUmTyujMNnpm90jdkjp8RpE_XfmNlhU6yJN-qbarE8NuExtlfpXCMvWwt6bMLOU28uWGMQAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-09-09","event_type":"ad_hoc","title":"BioVersys reports half-year 2026 results: BV100 pivotal RIV ...","category":"ad-hoc","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/ad-hoc/bioversys-reports-half-year-2026-results-bv100-pivotal-riv-target-trial-actively-recruiting-alpibectir-phase-2b-c-underway-operations-funded-into-2028/b1979958-6896-4f23-aed5-0fb65e3d4b76_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"2wh4VHt9V7-nWqNeQQ25lK_1T4WpXLsgoZURnGycPFcgTP2b5WHq52W1uSHXxJvJ2w3e_R61YH7HqZ-Iqn38DQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-09-09","event_type":"corporate_news","title":"BioVersys reports half-year 2026 results: BV100 pivotal RIV-TARGET trial actively recruiting, alpibectir Phase 2b/c underway, operations funded into 2028","source":"issuer news (Grok)","url":"https://www.eqs-news.com/news/ad-hoc/bioversys-reports-half-year-2026-results-bv100-pivotal-riv-target-trial-actively-recruiting-alpibectir-phase-2b-c-underway-operations-funded-into-2028/b1979958-6896-4f23-aed5-0fb65e3d4b76_en","read_by":"read by Grok (live)","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"w95Bsv0HorT0DKrCL2sTmLHhpAem1V5l7_aY8PvjEdM6mSQg2cMLt1H2ai3401yIQwzxlJ17O2QV8MW-1CEOAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-06-26","event_type":"register_mutation","title":"HR02 Change BioVersys AG, Basel","reference":"HR02-1006689609","category":"HR02","language":"de","source":"SHAB / FOSC commercial register publication","url":"https://www.shab.ch/#!/search/publications/detail/512224be-ffb8-410d-8384-083957da0da7","read_by":"SHAB publications API (Swiss Official Gazette of Commerce, commercial-register rubric)","detail":"publication HR02-1006689609; office Bundesamt für Justiz (BJ), Eidgenössisches Amt für das Handelsregister","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"5qU7E5yCHG6QOe9IAVy7Ge3CcQ42txdAffthdFVBpkxzd30NkhsllMXjDLTdz62ZmuW78JqTwU-ryv-zq1KFBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-04-16","event_type":"newswire_release","title":"BioVersys Announces First Patient First Visit in HABP/VABP","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/16/3275014/0/en/bioversys-announces-first-patient-first-visit-in-habp-vabp-pivotal-phase-3-riv-target-trial-of-bv100.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"9p6a6xaNAm4p739daiKGXamN-X7XcPkxj4EVV9A3obyYieoe5ImDFLVTWb_7rFiS4PtOWghmuMzdqlsE6e7gDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-04-15","event_type":"corporate_news","title":"BioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026 | Corporate - EQS News","category":"corporate","language":"en","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/bioversys-to-present-data-on-clinical-and-preclinical-pipeline-programs-at-escmid-global-2026/92a06921-f59f-42ae-9cfb-b26a1ca3db0a_en","read_by":"Tavily search (eqs-news.com) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"3cMH3Igz9hWdSEQEgJvCs2T9lzu1GTyBi0jOULNqOApZk3mu1_qG1JVcnexIkkPMoqF6E538CUHFaLepl84yDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-04-15","event_type":"newswire_release","title":"BioVersys to present data on clinical and preclinical pipeline ...","wire":"EQS News","source":"EQS News","url":"https://www.eqs-news.com/news/corporate/bioversys-to-present-data-on-clinical-and-preclinical-pipeline-programs-at-escmid-global-2026/92a06921-f59f-42ae-9cfb-b26a1ca3db0a_en","read_by":"Tavily search (wire domains) + published_date · adjudicated by Claude","state":"sourced","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"nkbVzNhEqjagS6CyUpu-BR_DXFrzIUNp9WGn7cMhaV41cyrIbYQUNee3cx7C9DN13v0sPzp6ijGDu8TBNBAFDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-04-15","event_type":"newswire_release","title":"BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/15/3274109/0/en/BioVersys-to-Present-Data-on-Clinical-and-Preclinical-Pipeline-Programs-at-ESCMID-Global-2026.html","read_by":"Tavily search (wire domains) + published_date · adjudicated by Claude","state":"sourced","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"iQ8vJ7bI7QCP6XW_y2Fp0OXpXDtIOjzh5D2oHypIkNY-vvvMmNcNBurFdM0OtyctwfFHVs_5lmv20dqeOcOoDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-03-31","event_type":"newswire_release","title":"BioVersys Strengthens Ansamycin Platform and NTM Research","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/03/31/3265142/0/en/bioversys-strengthens-ansamycin-platform-and-ntm-research-through-collaboration-and-license-agreement-with-hackensack-meridian-health.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"d_-mumqoiYCpUHDUZLUhxAEEY12ndbS5ELjV9zUt_QZb6yqAVBhakY4nSH2eqwXVQdUgcTZNm1Q0eQ2vuYo8Ag","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-03-18","event_type":"results","title":"BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/03/18/3257882/0/en/BioVersys-Reports-Corporate-Highlights-and-Financial-Results-for-the-Full-Year-2025.html","read_by":"Tavily search (wire domains) + published_date · adjudicated by Claude","state":"sourced","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"9i0zF-0hNg_wEgxhJGk0Y3WBz8XQcttQSQYDJnZpqfD73WfNT88-QvEPLu4M0iEJkMmU2H3jVxCDIHEeK-lKCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-03-12","event_type":"newswire_release","title":"BioVersys Announces First Patient Dosed in Phase 2b","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/03/12/3254275/0/en/bioversys-announces-first-patient-dosed-in-phase-2b-clinical-trial-of-alpe-in-pulmonary-tuberculosis.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"W4Nf-uO2qdBEp9muKyjUtmSi7a2K_1LJdFAfbkifPWFBpRqmC317wjEsLeU0SbU55kWlNsEjvk6LcO08b1SsAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-03-04","event_type":"newswire_release","title":"BioVersys Announces Publication of BV100 Phase 1 Clinical","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/03/04/3249041/0/en/bioversys-announces-publication-of-bv100-phase-1-clinical-data-in-journal-of-antimicrobial-agents-and-chemotherapy.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"wb2mQrvFxe733MGhQnpXMXqMPnqrBgMrGJOF2zfjeN2uIWEYepVrbBdzseNCx6d-cVXW4wcqQYplmBgf8UpJDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-02-19","event_type":"newswire_release","title":"BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/02/19/3240756/0/en/bioversys-and-partners-phase-2a-tuberculosis-trial-results-published-in-new-england-journal-of-medicine.html","read_by":"Tavily search (wire domains) + published_date · adjudicated by Claude","state":"sourced","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"rXZoBQCcJT_JuWXpGlZMeINu4YNzaMM3-xLEtqw2Y5aoKd-DaHfHyWW6rFzvZxdtT1ycNJHyPCPW6Q8CFrr5AA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-01-14","event_type":"register_mutation","title":"HR02 Change BioVersys AG, Basel","reference":"HR02-1006538274","category":"HR02","language":"de","source":"SHAB / FOSC commercial register publication","url":"https://www.shab.ch/#!/search/publications/detail/9ada523e-81cd-4b5c-8b4d-d4080b3d9f75","read_by":"SHAB publications API (Swiss Official Gazette of Commerce, commercial-register rubric)","detail":"publication HR02-1006538274; office Bundesamt für Justiz (BJ), Eidgenössisches Amt für das Handelsregister","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"OZZc93Cn091WMjLQKFSM7bUffjmDDG-4pTSw_s7oVj93XrpGs7bw0rVoG_iqbaZ6WU058TIV9J1o3aGchmDVDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2026-01-05","event_type":"register_mutation","title":"HR02 Change BioVersys AG, Basel","reference":"HR02-1006528699","category":"HR02","language":"de","source":"SHAB / FOSC commercial register publication","url":"https://www.shab.ch/#!/search/publications/detail/6707fe07-8612-49a7-a8e9-bb4d1c6dff44","read_by":"SHAB publications API (Swiss Official Gazette of Commerce, commercial-register rubric)","detail":"publication HR02-1006528699; office Bundesamt für Justiz (BJ), Eidgenössisches Amt für das Handelsregister","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"LzbtsbF45j0c1v54UM6BVR4JoP5z8IWGf67tfxxnQcnaa9OwvC5B5JwVI96OxwghcMubtTz2QtYVYhRIJj4rDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2025-12-11","event_type":"newswire_release","title":"BioVersys Announces BV100 Phase 3 Initiation and Provides a","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2025/12/11/3203614/0/en/BioVersys-Announces-BV100-Phase-3-Initiation-and-Provides-a-Business-Update.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"OHNEoM2n4GagLPwAR276piL_z18GX5SAyLAdZyQLaTf8Mi93Cq47lcfEE3X8oY0m8sqlY8I7XGDIkXhwF3SMDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"ch-cm-kg/SIX/BIOV","date":"2025-10-07","event_type":"register_mutation","title":"HR02 Change BioVersys AG, Basel","reference":"HR02-1006451627","category":"HR02","language":"de","source":"SHAB / FOSC commercial register publication","url":"https://www.shab.ch/#!/search/publications/detail/f903ad98-ff4a-4da9-969f-365f2725ef16","read_by":"SHAB publications API (Swiss Official Gazette of Commerce, commercial-register rubric)","detail":"publication HR02-1006451627; office Bundesamt für Justiz (BJ), Eidgenössisches Amt für das Handelsregister","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"WiyGLxjCeQNCFatlIIJtbO-tm7G4y1320oWrHSzyE3IcHbNzRiZgqot3FvUL2sO3HO-VoZfn0lawWcjygue1DQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}}],"events_signed":"allooloo-cmr-2026-10"}